10-Q Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 Q2 2019

Filing Information

Form Type	10-Q
Accession Number	`0001193125-19-215317`
Period End Date	20190630
Filing Date	20190807
Fiscal Year	2019
Fiscal Period	Q2
XBRL Instance	d768753d10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 82 Income Statement 95 Cash Flow Statement 61 Stockholders Equity 27 Comprehensive Income 36

Balance Sheet 82 line items

Line Item	Tag	Value	Unit	Period
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Common stock, par or stated value per share	`CommonStockParOrStatedValuePerShare`	0.10	ILS	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, authorized	`CommonStockSharesAuthorized`	2.50B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Ordinary shares, issued	`CommonStockSharesIssued`	1.20B	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.78B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.17B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.26B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	107.00M	shares	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$5.82B	USD	Point-in-time
Treasury shares	`TreasuryStockShares`	106.00M	shares	Point-in-time
Inventories	`InventoryNet`	$4.73B	USD	Point-in-time
Inventories	`InventoryNet`	$4.85B	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$899.00M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.07B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$468.00M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$437.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$24.00M	USD	Point-in-time
Assets held for sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$92.00M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.80B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.79B	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$317.00M	USD	Point-in-time
Deferred income taxes	`DeferredTaxAssetsNetNoncurrent`	$368.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$731.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$721.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.73B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$6.87B	USD	Point-in-time
Operating lease right-of-use assets	`OperatingLeaseRightOfUseAsset`	$500.00M	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$12.44B	USD	Point-in-time
Identifiable intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$14.01B	USD	Point-in-time
Goodwill	`Goodwill`	$24.92B	USD	Point-in-time
Goodwill	`Goodwill`	$24.91B	USD	Point-in-time
Total assets	`Assets`	$59.42B	USD	Point-in-time
Total assets	`Assets`	$60.68B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.77B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$2.22B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.05B	USD	Point-in-time
Sales reserves and allowances	`SalesReservesAndAllowances`	$6.71B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.81B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.85B	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$870.00M	USD	Point-in-time
Employee-related obligations	`EmployeeRelatedLiabilitiesCurrent`	$587.00M	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$1.87B	USD	Point-in-time
Accrued expenses	`AccruedExpenses`	$2.33B	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$804.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$899.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.32B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$14.45B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$1.70B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$2.14B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.64B	USD	Point-in-time
Other taxes and long-term liabilities	`OtherLiabilitiesNoncurrent`	$1.73B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$26.70B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$25.95B	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$426.00M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$30.57B	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$29.72B	USD	Point-in-time
Total liabilities	`Liabilities`	$44.17B	USD	Point-in-time
Total liabilities	`Liabilities`	$44.89B	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Ordinary shares of NIS 0.10 par value per share; June 30, 2019 and December 31, 2018: authorized 2,495 million shares; issued 1,198 million shares and 1,196 million shares, respectively	`CommonStockValue`	$56.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.21B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$27.26B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-6.75B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-5.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.31B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-2.46B	USD	Point-in-time
Treasury shares as of June 30, 2019 and December 31, 2018 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.13B	USD	Point-in-time
Treasury shares as of June 30, 2019 and December 31, 2018 107 million ordinary shares and 106 million ordinary shares, respectively	`TreasuryStockValue`	$4.14B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.71B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$14.12B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.09B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.13B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$60.68B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$59.42B	USD	Point-in-time

Income Statement 95 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$9.77B	USD	2 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.70B	USD	1 Quarter
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$8.63B	USD	2 Qtrs
Net revenues	`RevenueFromContractWithCustomerExcludingAssessedTax`	$4.34B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$4.88B	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$2.67B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$2.44B	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$5.42B	USD	2 Qtrs
Gross profit	`GrossProfit`	$1.89B	USD	1 Quarter
Gross profit	`GrossProfit`	$4.35B	USD	2 Qtrs
Gross profit	`GrossProfit`	$3.75B	USD	2 Qtrs
Gross profit	`GrossProfit`	$2.03B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$607.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$276.00M	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$537.00M	USD	2 Qtrs
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$290.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$666.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.31B	USD	2 Qtrs
Selling and marketing expenses	`SellingAndMarketingExpense`	$682.00M	USD	1 Quarter
Selling and marketing expenses	`SellingAndMarketingExpense`	$1.42B	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$645.00M	USD	2 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$296.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$316.00M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$589.00M	USD	2 Qtrs
Intangible assets impairment	`IntangibleAssetsImpairments`	$727.00M	USD	2 Qtrs
Intangible assets impairment	`IntangibleAssetsImpairments`	$561.00M	USD	1 Quarter
Intangible assets impairment	`IntangibleAssetsImpairments`	$1.03B	USD	2 Qtrs
Intangible assets impairment	`IntangibleAssetsImpairments`	$521.00M	USD	1 Quarter
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$120.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$194.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$695.00M	USD	2 Qtrs
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$101.00M	USD	1 Quarter
Other assets impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$103.00M	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$646.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$703.00M	USD	2 Qtrs
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$20.00M	USD	1 Quarter
Legal settlements and loss contingencies	`LegalSettlementsAndLossContingencies`	$-1.26B	USD	2 Qtrs
Other income	`OtherIncome`	$299.00M	USD	2 Qtrs
Other income	`OtherIncome`	$96.00M	USD	1 Quarter
Other income	`OtherIncome`	$15.00M	USD	2 Qtrs
Other income	`OtherIncome`	$9.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-510.00M	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$1.51B	USD	2 Qtrs
Operating income (loss)	`OperatingIncomeLoss`	$-14.00M	USD	1 Quarter
Operating income (loss)	`OperatingIncomeLoss`	$-644.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-425.00M	USD	2 Qtrs
Financial expenses, net	`NonoperatingIncomeExpense`	$-206.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-236.00M	USD	1 Quarter
Financial expenses, net	`NonoperatingIncomeExpense`	$-507.00M	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$1.00B	USD	2 Qtrs
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-250.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-850.00M	USD	1 Quarter
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-934.00M	USD	2 Qtrs
Income taxes	`IncomeTaxExpenseBenefit`	$-170.00M	USD	2 Qtrs
Income taxes	`IncomeTaxExpenseBenefit`	$-179.00M	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$-76.00M	USD	1 Quarter
Income taxes	`IncomeTaxExpenseBenefit`	$-30.00M	USD	2 Qtrs
Share in losses (income) of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-4.00M	USD	2 Qtrs
Share in losses (income) of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$8.00M	USD	1 Quarter
Share in losses (income) of associated companies, net	`IncomeLossFromEquityMethodInvestments`	$-66.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$18.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$10.00M	USD	1 Quarter
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$24.00M	USD	2 Qtrs
Net income attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$26.00M	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-794.00M	USD	2 Qtrs
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-689.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-176.00M	USD	1 Quarter
Net income (loss) attributable to Teva	`NetIncomeLoss`	$944.00M	USD	2 Qtrs
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$65.00M	USD	1 Quarter
Dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$130.00M	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-241.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-794.00M	USD	2 Qtrs
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-689.00M	USD	1 Quarter
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$814.00M	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-0.73	USD	2 Qtrs
Basic	`EarningsPerShareBasic`	$-0.63	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-0.24	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.80	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.24	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-0.73	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$0.80	USD	2 Qtrs
Diluted	`EarningsPerShareDiluted`	$-0.63	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	2 Qtrs
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.09B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	1 Quarter
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.02B	shares	2 Qtrs
Diluted	`WeightedAverageNumberOfDilutedSharesOutstanding`	1.09B	shares	2 Qtrs

Cash Flow Statement 61 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.27B	USD	2 Qtrs
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$1.06B	USD	2 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$1.10B	USD	2 Qtrs
Impairment of long-lived assets	`AssetImpairmentCharges`	$980.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$986.00M	USD	2 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$893.00M	USD	2 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-489.00M	USD	2 Qtrs
Deferred income taxes net and uncertain tax positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-362.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$64.00M	USD	2 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$77.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-11.00M	USD	2 Qtrs
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-44.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$-6.00M	USD	2 Qtrs
Net gain from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$88.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$300.00M	USD	2 Qtrs
Goodwill impairment	`GoodwillImpairmentLoss`	$120.00M	USD	1 Quarter
Impairment of equity investment	`ImpairmentOfInvestments`	$94.00M	USD	2 Qtrs
In process Research and development	`ResearchAndDevelopmentExpense`	$54.00M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$1.66B	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-115.00M	USD	2 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$970.00M	USD	2 Qtrs
Beneficial interest collected in exchange for securitized trade receivables	`ProceedsFromBeneficialInterestInExchangeForSecuritizedTradeReceivables`	$746.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$299.00M	USD	2 Qtrs
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$237.00M	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$841.00M	USD	2 Qtrs
Proceeds from sales of business, investments and long-lived assets	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$134.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$-59.00M	USD	2 Qtrs
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$11.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$1.00M	USD	2 Qtrs
Purchases of investments and other assets	`PaymentToAcquireMarketableSecuritiesAndOtherAssets`	$56.00M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$701.00M	USD	2 Qtrs
Net cash provided by investing activities	`NetCashProvidedByUsedInInvestingActivities`	$1.45B	USD	2 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$157.00M	USD	2 Qtrs
Repayment of senior notes and loans and other long-term liabilities	`RepaymentsOfLongTermDebt`	$6.29B	USD	2 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$22.00M	USD	2 Qtrs
Tax withholding payments made on shares and dividends	`PaymentsRelatedToTaxWithholdingForSharesAndDividend`	$52.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-13.00M	USD	2 Qtrs
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-10.00M	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-261.00M	USD	2 Qtrs
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-2.00M	USD	2 Qtrs
Proceeds from senior notes and loans, net of issuance costs	`ProceedsFromDebtNetOfIssuanceCosts`	$4.43B	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-224.00M	USD	2 Qtrs
Net cash used in financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.15B	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-58.00M	USD	2 Qtrs
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$21.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$898.00M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$383.00M	USD	2 Qtrs
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.17B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.86B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$2.17B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.86B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$1.78B	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$770.00M	USD	Point-in-time
Beneficial interest obtained in exchange for securitized trade receivables	`BeneficialInterestObtainedInExchangeForSecuritizedTradeReceivables`	$968.00M	USD	Point-in-time

Stockholders Equity 27 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-780.00M	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-595.00M	USD	1 Quarter
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$550.00M	USD	2 Qtrs
Comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-598.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$64.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$32.00M	USD	1 Quarter
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$77.00M	USD	2 Qtrs
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$47.00M	USD	1 Quarter
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$6.00M	USD	2 Qtrs
Issuance of Treasury Shares	`TreasuryStockValueAcquiredCostMethod`	$3.00M	USD	1 Quarter
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$8.00M	USD	1 Quarter
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$8.00M	USD	2 Qtrs
Transactions with non-controlling interests	`TransactionsWithNonControllingInterests`	$2.00M	USD	2 Qtrs
Other	`OtherEquity`	$-2.00M	USD	1 Quarter
Other	`OtherEquity`	$-8.00M	USD	2 Qtrs
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.79B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$20.10B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.25B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$15.82B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.37B	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time

Comprehensive Income 36 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-671.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-166.00M	USD	1 Quarter
Net income (loss)	`ProfitLoss`	$-768.00M	USD	2 Qtrs
Net income (loss)	`ProfitLoss`	$968.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-472.00M	USD	2 Qtrs
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$86.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-711.00M	USD	1 Quarter
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$133.00M	USD	2 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-100.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$10.00M	USD	1 Quarter
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-56.00M	USD	2 Qtrs
Unrealized gain (loss) from derivative financial instruments	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-37.00M	USD	2 Qtrs
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	1 Quarter
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$1.00M	USD	2 Qtrs
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	2 Qtrs
Unrealized gain (loss) from available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-1.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	1 Quarter
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-1.00M	USD	2 Qtrs
Unrealized loss on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-2.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$170.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$76.00M	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-418.00M	USD	2 Qtrs
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$-614.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-780.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-595.00M	USD	1 Quarter
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$550.00M	USD	2 Qtrs
Total comprehensive income (loss)	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-598.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$46.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$-51.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$47.00M	USD	1 Quarter
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest`	$49.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-642.00M	USD	1 Quarter
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$504.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-647.00M	USD	2 Qtrs
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTax`	$-729.00M	USD	1 Quarter

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.